Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Equity (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Return on Equity for 5 consecutive years, with 0.4% as the latest value for Q1 2026.

  • For Q1 2026, Return on Equity fell 77.0% year-over-year to 0.4%; the TTM value through Mar 2026 reached 0.4%, down 77.0%, while the annual FY2025 figure was 0.64%, 141.0% down from the prior year.
  • Return on Equity hit 0.4% in Q1 2026 for Phathom Pharmaceuticals, down from 0.51% in the prior quarter.
  • Across five years, Return on Equity topped out at 2043.99% in Q3 2023 and bottomed at 0.4% in Q1 2026.
  • Average Return on Equity over 5 years is 147.88%, with a median of 1.58% recorded in 2024.
  • Year-over-year, Return on Equity surged 55bps in 2023 and then tumbled -204238bps in 2024.
  • Phathom Pharmaceuticals' Return on Equity stood at 3.9% in 2022, then grew by 14bps to 4.45% in 2023, then plummeted by -66bps to 1.52% in 2024, then crashed by -66bps to 0.51% in 2025, then fell by -21bps to 0.4% in 2026.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.4%, 0.51%, and 0.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.